Status | Study |
Recruiting |
Study Name: Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2014-12-05 Interventions: Drug: Rituximab, Methotrexate, Temozolomide Seven monthly R-MT cycles including high dose MTX (3.5g/m2, |
Completed |
Study Name: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Condition: Lymphoma Primary Central Nervous System Lymphoma Date: 2014-11-21 Interventions: Drug: Buparlisib (BKM120) Buparlisib 100 mg once daily. |
Enrolling by invitation |
Study Name: Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Condition: Primary Central Nervous System Lymphoma Date: 2014-04-23 Interventions: Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
Terminated |
Study Name: Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2014-04-10 Interventions: Drug: Rituximab plus Temozolomide Treatment cycles will be repeated every 14 days (2 weeks) for the lead |
Recruiting |
Study Name: Treatment of Primary CNS Lymphoma Condition: Primary CNS Lymphoma (PCNSL) Date: 2013-10-08 Interventions: Drug: HD-MTX-Ara-C regimen hig |
Recruiting |
Study Name: Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Condition: Recurrent or Refractory Primary CNS Lymphoma Date: 2009-07-20 Interventions: Drug: temsirolimus Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all oth |
Active, not recruiting |
Study Name: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients Condition: Primary Central Nervous System Lymphoma Date: 2009-03-16 Interventions: Radiation: cranial radiotherapy |
Withdrawn |
Study Name: Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2008-07-03 Interventions: Drug: Pemetrexed 500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until pr |
Terminated |
Study Name: Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors Condition: Primary Central Nervous System Lymphoma (PCNSL) Date: 2008-07-02 |
Withdrawn |
Study Name: a Phase II Study in Primary Central Nervous System Lymphoma Condition: Primary Central Nervous System Lymphoma Date: 2007-04-02 Interventions: Drug: Methotrexate Drug: Methylprednisolon |